Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen

Clinical and Experimental Immunology

Volumn 144, Issue 3, 2006, Pages 521-527

  Paulovicova E ^a   Machova E ^a   Hostacka A ^b   Bystricky S ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Research Base of the Slovak Medical University   (Slovakia)

Author keywords

Complex conjugate; Immunization; Immunoglobulins; Lipopolysaccharide; T cell response; V. cholerae O1 Ogawa

Indexed keywords

AMYLOSE; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT; GLUCAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOMODULATING AGENT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CELLULAR IMMUNITY; CONJUGATE; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE MUCOSA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; VIBRIO CHOLERAE;

ADJUVANTS, IMMUNOLOGIC; AMYLOSE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; CHOLERA VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; TH1 CELLS; VACCINES, CONJUGATE; VIBRIO CHOLERAE O1;

EID: 33744476668     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03077.x     Document Type: Article

References (24)

1. Taylor RK, Kim TJ, Bose N, et al. Progress towards development of a cholera subunit vaccine. Chem Biodiversity 2004 7 : 1036 57.
2. Egan W. The development and current status of glycoconjugate vaccines. Ann Rep Med Chem 1993 28 : 257 65.
3. Olowokure B, Hawker J, Blair I, Spencer N. Decrease in effectiveness of routine surveillance of Haemophilus influenzae disease after introduction of conjugate vaccine: comparison of routine reporting with active surveillance system. BMJ 2000 321 : 731 2.
4. Qadri F, Ahmed F, Karim MM et al. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B cell responses in cholera. Clin Diagn Lab Immunol 1999 6 : 812 8.
5. Alexander J, del Guercio MF, Frame B et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®). Vaccine 2004 22 : 2362 7.
6. Wang J, Villeneuve S, Zhang J. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O1 serotypes Ogawa and Inaba. J Biol Chem 1998 273 : 2777 83.
7. Ogawa Y, Lei PS, Kovac P. Synthesis of eight glycosides of hexasaccharide fragments representing the terminus of the O-polysaccharide of Vibrio cholerae O1, serotype Inaba and Ogawa, bearing aglycons suitable for linking to proteins. Carbohydr Res 1996 293 : 173 94.
8. Ogawa Y, Kovac P. Synthesis of the dodecasaccharide fragment representing the O-polysaccharide of Vibrio cholerae O1, serotype Ogawa, bearing an aglycon offering flexibility for chemical linking to proteins. Glycoconj J 1997 14 : 433 8.
9. Chernyak A, Kondo S, Wade TK et al. Induction of protective immunity by synthetic Vibrio cholerae hexasaccharide derived from V. cholerae O1 Ogawa lipopolysaccharide bound to a protein carrier. J Infect Dis 2002 185 : 950 62.
10. Gupta RK, Szu SC, Finkelstein RA, Robbins JB. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio-cholerae O1 serotype Inaba bound to cholera-toxin. Infect Immun 1992 60 : 3201 8.
11. Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 1998 66 : 3095 9.
12. Machová E, Bystrický S, Gáliková A, Kogan G. Preparation of a subcellular conjugate with the lipopolysaccharide from Vibrio cholerae O1 using beta-D-glucan as matrix. Eur J Med Chem 2000 237 : 681 7.
13. Orlando M. Modification of proteins and low molecular weight sunstances with hydroxyethylstarch (HES). Inaugural dissertation, Geisen, 2003.
14. Battle J, Ha T, Li C et al. Ligand binding to the (1→3) β-D-glucan receptor stimulates NFκB activation, but not apoptosis in U937 cells. Biochem Biophys Res Commun 1998 249 : 499 504.
15. Tokunaka K, Ohno N, Adachi Y, Miura NN, Yadomae T. Application of Candida solubilized cell wall β-glucan in antitumor immunotherapy against P815 mastocytoma in mice. Int Immunopharmacol 2002 2 : 59 67.
16. Tsiapali E, Whaley S, Kalbfleisch JHE, Ensley W, Browder J, Williams DL. Glucans exhibited weak antioxidant activity, but stimulate macrophage free radical activity. Free Rad Biol Med 2001 30 : 393 402.
17. Quadri F, Mohi G, Hossain J et al. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol 1995 2 : 685 8.
18. Zhang J, Kováč P. Studies on vaccines against cholera. Synthesis of neoglycoconjugates from the hexasaccharide determinant of Vibrio cholerae O1, serotype Ogawa, by single-point attachment or by attachment of the hapten in the form of clusters. Carbohydr Res 1999 321 : 157 67.
19. Robbins JB, Schneerson R, Szu SC. Perspective-hypothesis-serum IgG antibody is sufficient to confer protection against infectious-diseases by inactivating the inoculum. J Infect Dis 1995 171 : 1387 98.
20. Szu SC, Gupta RK, Robbins JB. Induction of serum vibriocidal antibodies by O-specific polysaccharide-protein conjugate vaccines for prevention of cholera. In : Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera. Molecular to global perspectives. Washington, DC : American Society for Microbiology, 1994 : 381 94.
21. Bradwell AR. IgG and IgA subclasses in disease. Birmingham : The Binding Site Ltd, 1995 : 118 35.
22. Nilssen DE, Friman V, Theman K et al. Intestinal immunoglobulin production after oral cholera vaccination in patients with IgA deficiency with or without IgG subclass deficiency. Immunodeficiency 1993 4 : 55 7.
23. Suzuki Y, Adachi Y, Ohno N, Yadomae T. Th1/Th2-balancing immunomodulating activity of gel-forming (1→3) -β-glucans from fungi. Biol Pharm Bull 2001 24 : 811 19.
24. Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin F-Y, Gotschlich EC. Standardization may suffice for licensure of conjugate vaccines. In : Plotkin S, Brown F, Horaud F, eds. Preclinical and chemical development of new vaccines, Vol. 95. Developments in Biological Standardization. Basel : Karger, 1998 : 161 7.